Shares of Alterity Therapeutics ATHE were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for ...
STOCKHOLM, May 8, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that regulatory authorities in Spain in Poland have approved the inclusion of Multiple System ...
At last night’s Michigan Student Assembly meeting, MSA representatives introduced three new resolutions and addressed six resolutions that were proposed at previous meetings. One of the proposals was ...
The Maryland Stadium Authority wants Baltimore City to help pay for a feasibility study on a proposed expanded convention center, new arena and hotel for downtown Baltimore. The MSA voted Tuesday to ...
>The summer of 2004 marked the beginning of the University’s strategic positioning to become one of the top three public research universities. At the time, this idea of transformation seemed very ...
Multiple system atrophy (MSA) is a sporadic and rare neurodegenerative movement disorder with an estimated annual incidence of 0.6 per 100,000 (ORPHA102) The clinical presentation is highly variable, ...
The goal is to develop a disease modifying treatment that stops or slow down the progression of alpha-synucleinopathies e.g. Parkinson's disease and MSA. BioArctic's phase 2a study EXIST with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback